Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PRTA logo PRTA
Upturn stock ratingUpturn stock rating
PRTA logo

Prothena Corporation plc (PRTA)

Upturn stock ratingUpturn stock rating
$6.07
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: PRTA (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

10 Analysts rated it

Well-followed company, solid analyst reports, reliable data for confident investing.

1 Year Target Price $24.29

1 Year Target Price $24.29

Analysts Price Target For last 52 week
$24.29Target price
Low$4.32
Current$6.07
high$25.42

Analysis of Past Performance

Type Stock
Historic Profit -24.41%
Avg. Invested days 16
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 328.88M USD
Price to earnings Ratio -
1Y Target Price 24.29
Price to earnings Ratio -
1Y Target Price 24.29
Volume (30-day avg) 10
Beta -0.08
52 Weeks Range 4.32 - 25.42
Updated Date 06/30/2025
52 Weeks Range 4.32 - 25.42
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.04

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -79.94%
Operating Margin (TTM) -2318.99%

Management Effectiveness

Return on Assets (TTM) -15.49%
Return on Equity (TTM) -23.46%

Valuation

Trailing PE -
Forward PE 64.1
Enterprise Value -81002220
Price to Sales(TTM) 2.38
Enterprise Value -81002220
Price to Sales(TTM) 2.38
Enterprise Value to Revenue 2.82
Enterprise Value to EBITDA -3.58
Shares Outstanding 53827000
Shares Floating 40657673
Shares Outstanding 53827000
Shares Floating 40657673
Percent Insiders 19.01
Percent Institutions 74.25

Analyst Ratings

Rating 4
Target Price 24.29
Buy 3
Strong Buy 5
Buy 3
Strong Buy 5
Hold 2
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Prothena Corporation plc

stock logo

Company Overview

overview logo History and Background

Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery and development of novel therapies to treat diseases that involve protein misfolding or cell adhesion. Founded in 2012 as a spin-off from Elan Corporation, Prothena initially focused on Alzheimer's disease and Parkinson's disease. Over time, it has expanded its pipeline to include therapies for other neurodegenerative and rare peripheral amyloid diseases.

business area logo Core Business Areas

  • Neurodegenerative Diseases: Development of therapies targeting neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.
  • Peripheral Amyloid Diseases: Development of therapies for rare peripheral amyloid diseases like AL amyloidosis and ATTR amyloidosis.

leadership logo Leadership and Structure

Gene Kinney, Ph.D., is the President and Chief Executive Officer. The company has a standard corporate structure with a board of directors and various executive leadership positions overseeing research and development, clinical operations, and business development.

Top Products and Market Share

overview logo Key Offerings

  • Birtamimab (PRX004): A monoclonal antibody designed to neutralize soluble amyloid light chain (AL) protein aggregates in AL amyloidosis. Phase 3 PRONTO study did not meet primary endpoint. Competitors include Johnson & Johnson (Tremfya) and Takeda (Vyvgart). As of November 2024, no market share is available as the drug is not approved.
  • PRX012: A potential best-in-class high potency anti-amyloid beta (Au03b2) antibody in development for the treatment of Alzheimeru2019s disease. Clinical trials are ongoing. Competitors include Eisai/Biogen (Leqembi), Eli Lilly (Donanemab). Market share is not applicable at this development stage.

Market Dynamics

industry overview logo Industry Overview

The biotechnology industry focused on neurodegenerative and rare diseases is characterized by high risk, long development timelines, and substantial investment. The market for Alzheimer's disease and Parkinson's disease therapies is large and growing due to an aging population. The market for rare diseases is smaller but offers opportunities for orphan drug designation and premium pricing.

Positioning

Prothena is positioned as a company focused on developing novel therapies using its expertise in protein misfolding and cell adhesion. It aims to differentiate itself through innovative approaches and targeting specific disease mechanisms.

Total Addressable Market (TAM)

The TAM for Alzheimer's and Parkinson's diseases alone is estimated to be tens of billions of dollars annually. Prothena is aiming to capture a significant portion of this market with its PRX012 and other pipeline assets. The TAM for AL amyloidosis is smaller, but still significant due to high unmet need. The PRONTO study results will determine if Prothena can capture that portion of the market.

Upturn SWOT Analysis

Strengths

  • Strong scientific expertise in protein misfolding and cell adhesion
  • Innovative pipeline of novel therapies
  • Experienced management team
  • Focus on unmet medical needs

Weaknesses

  • High reliance on clinical trial outcomes
  • Limited commercial infrastructure
  • Dependence on partnerships for funding and development
  • Recent Phase 3 Trial failure

Opportunities

  • Potential for breakthrough therapies in Alzheimer's disease and Parkinson's disease
  • Expansion of pipeline through strategic collaborations and acquisitions
  • Orphan drug designation for rare disease programs
  • Positive clinical results could lead to significant revenue growth

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from established pharmaceutical companies
  • Patent challenges
  • Uncertainty of R&D investment returns

Competitors and Market Share

competitor logo Key Competitors

  • ESAI (ESALY)
  • LLY (LLY)
  • BIIB (BIIB)
  • JNJ (JNJ)
  • TAK (TAK)

Competitive Landscape

Prothena faces strong competition from large pharmaceutical companies with established pipelines and commercial infrastructure. Its competitive advantage lies in its novel therapeutic approaches and expertise in protein misfolding. Market share for amyloidosis treatment is divided by competitors. Market share related to AD is rapidly evolving and dependent on safety and efficacy of treatments.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been dependent on preclinical results and partnership collaborations.

Future Projections: Future growth is largely dependent on clinical trial results for PRX012 and other pipeline assets. Analyst estimates vary widely based on perceived probability of success.

Recent Initiatives: Focus on advancing PRX012 into late-stage clinical trials and expanding partnerships to fund development programs.

Summary

Prothena is a clinical-stage biotech firm with a focus on high-risk, high-reward therapies for neurodegenerative and rare diseases. Its innovative approach to protein misfolding offers promise, but it relies heavily on successful clinical trials. Recent negative data for Birtamimab will impact the company valuation until new, positive data arises. Continued partnership and R&D execution are critical for future growth, while competition from large pharmaceuticals remains a significant challenge.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports

Disclaimers:

The data provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Prothena Corporation plc

Exchange NASDAQ
Headquaters -
IPO Launch date 2012-12-21
President, CEO & Director Dr. Gene G. Kinney Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 163
Full time employees 163

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.